APST is a digital platform for care management and medical research. We provide a care network for people with severe and rare neurological diseases.
We facilitate the provision of appropriate medical aids, remedies, medicines and nutritional support.
We link specialized doctors, therapists, medical supply stores and pharmacies to provide individual care solutions.
We explore treatment realities and care outcomes through systematic data analysis.
In a changing medicine, we aim to provide programs for specialized, individualized and more precise care.
The ALS Pharmacy Program offers specialized medication management and participation in medical research for people with amyotrophic lateral sclerosis.
The ALS care algorithm is meant to strengthen the physician-patient relationship. The algorithm has the potential to improve care for people with ALS.
The ALS app can be used to track the progression of ALS. People affected can participate in research and assist provision of care from home.
The effectiveness of Nusinersen is being evaluated in adults with SMA as to the achievement of treatment goals, symptom progression and the patient’s satisfaction with the treatment.
People with ALS are invited to participate in a research project on digital speech and facial expression analysis via the ALS app.
The SMA Pharmacy Program offers specialized drug treatment and participation in medical research for people with spinal muscular atrophy (SMA).
We conduct research aimed at establishing the biomarker neurofilament light chain (NF-L) as a criterion for assessing the urgency of care for people with ALS.
Latest news and background information from the APST network
On May 11, 2023, the APST ALS Network Meeting will take place in Berlin, followed directly by the MND-Net Meeting. The APST Network Meeting and the MND-Net Meeting serve to discuss current research and care in the field of ALS. The network meeting is attended by ALS experts, researchers and physicians from 14 German ALS outpatient clinics part. There ...
read moreWhy is the biomarker NfL important for people with ALS? The value of the biomarker Neurofilament light chain (NfL) in the blood is suitable for assessing the progression and therapy of ALS. A high blood serum NfL value is often associated with a higher speed in the progression of ALS symptoms. Two recent publications in March this year in the internat ...
read moreWe would like to briefly update you on the current status (03/01/2023) of the ID-ALS02 study and the transition to the Tofersen Hardship Program After the successful completion of the first part of the ID-ALS study, its continuation was started in October 2022. With the second part of the study (ID-ALS02), so far 1,476 patients with amyotrophic latera ...
read morePeople with ALS require individualized care depending on the course of the disease. In the course of the disease and depending on the affected body regions, the focus of care is on assessment, support or participation in life. The respective individual phase of care is recorded via the ALS Functional Scale.
One body region affected
King’s Stage 1Two body regions affected
King’s Stage 2Three body regions affected
King’s Stage 3Ventilation and/or feeding tube
King’s Stage 4Due to the relative rarity, progressive nature and complexity of ALS, specialization and digital networking of outpatient clinics are essential. Our network of specialised ALS centres started in 2010 and has been evolving ever since. The network is a group of outpatient clinics that are interested in providing good care for their ALS patients. The network supports each other with the exchange of information, the implementation of studies and professional coordination.
Case- and Network Management
Coordination, Specialization on ALS
Assistive devices coordinator, outreach care management
Data Management
Medical Research
Medical Research
Medical Research
Network and Trial Coordination